Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases

GJM Herder,1 H Codrington,2 CD Colder,3 JG Aerts4,51St Antonius Hospital, Nieuwegein, The Netherlands; 2Haga Hospital, The Hague, The Netherlands; 3St Jansdal Hospital, Harderwijk, The Netherlands; 4Amphia Hospital, Breda; 5Erasmus MC Rotterdam, The NetherlandsIntroduction: Previous research showed...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Herder GJM, Codrington H, Colder CD, Aerts JG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5b5fdb05a88e4542a6ff4adb45ba0468
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5b5fdb05a88e4542a6ff4adb45ba0468
record_format	dspace
spelling	oai:doaj.org-article:5b5fdb05a88e4542a6ff4adb45ba04682021-12-02T03:51:28ZPractical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases1179-2728https://doaj.org/article/5b5fdb05a88e4542a6ff4adb45ba04682013-10-01T00:00:00Zhttp://www.dovepress.com/practical-management-of-nsclc-patients-with-long-term-bevacizumab-trea-a14653https://doaj.org/toc/1179-2728GJM Herder,1 H Codrington,2 CD Colder,3 JG Aerts4,51St Antonius Hospital, Nieuwegein, The Netherlands; 2Haga Hospital, The Hague, The Netherlands; 3St Jansdal Hospital, Harderwijk, The Netherlands; 4Amphia Hospital, Breda; 5Erasmus MC Rotterdam, The NetherlandsIntroduction: Previous research showed that the addition of bevacizumab (a monoclonal antibody against vascular endothelial growth factor [VEGF]) to chemotherapy resulted in a significant efficacy benefit in the treatment of selected patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However, the occurrence and management of adverse events (AEs) during long-term maintenance treatment with bevacizumab is not well known.Methods: This report presents a descriptive analysis, including the management of AEs, of four patients with advanced NSCLC, who received a relatively long period of bevacizumab maintenance treatment.Results: In patient 1, a 72-year-old retired man with stage cT2N2M1b NSCLC, the only AE related to bevacizumab was a grade 1 rhinorrhea. Treatment resulted in a stable disease, with duration of response of 38 months. Patient 2 had NSCLC stage cT4N3M1b and developed a cavitation and infection after the first cycle of chemotherapy and bevacizumab, which caused a temporary decrease of her quality of life. Bevacizumab therapy resulted in a partial response, with duration of response of 15 months. A 52-year-old female (patient 3) with stage T2bN2M1a NSCLC is currently under treatment and has so far received 42 cycles of maintenance bevacizumab, with stabilized response (duration of response of 29 months) and no noteworthy AEs. The last patient is a 74-year-old male farmer with NSCLC T1N0M1, whose response has lasted for more than 3 years, with until now, no AEs.Conclusion: Our retrospective findings of these four patients show the long-term efficacy and safety of bevacizumab treatment in a real-life setting.Keywords: lung cancer, non–small cell lung cancer, maintenance treatment, safety managementHerder GJMCodrington HColder CDAerts JGDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2013, Iss default, Pp 55-59 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Herder GJM Codrington H Colder CD Aerts JG Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases
description	GJM Herder,1 H Codrington,2 CD Colder,3 JG Aerts4,51St Antonius Hospital, Nieuwegein, The Netherlands; 2Haga Hospital, The Hague, The Netherlands; 3St Jansdal Hospital, Harderwijk, The Netherlands; 4Amphia Hospital, Breda; 5Erasmus MC Rotterdam, The NetherlandsIntroduction: Previous research showed that the addition of bevacizumab (a monoclonal antibody against vascular endothelial growth factor [VEGF]) to chemotherapy resulted in a significant efficacy benefit in the treatment of selected patients with advanced nonsquamous non–small cell lung cancer (NSCLC). However, the occurrence and management of adverse events (AEs) during long-term maintenance treatment with bevacizumab is not well known.Methods: This report presents a descriptive analysis, including the management of AEs, of four patients with advanced NSCLC, who received a relatively long period of bevacizumab maintenance treatment.Results: In patient 1, a 72-year-old retired man with stage cT2N2M1b NSCLC, the only AE related to bevacizumab was a grade 1 rhinorrhea. Treatment resulted in a stable disease, with duration of response of 38 months. Patient 2 had NSCLC stage cT4N3M1b and developed a cavitation and infection after the first cycle of chemotherapy and bevacizumab, which caused a temporary decrease of her quality of life. Bevacizumab therapy resulted in a partial response, with duration of response of 15 months. A 52-year-old female (patient 3) with stage T2bN2M1a NSCLC is currently under treatment and has so far received 42 cycles of maintenance bevacizumab, with stabilized response (duration of response of 29 months) and no noteworthy AEs. The last patient is a 74-year-old male farmer with NSCLC T1N0M1, whose response has lasted for more than 3 years, with until now, no AEs.Conclusion: Our retrospective findings of these four patients show the long-term efficacy and safety of bevacizumab treatment in a real-life setting.Keywords: lung cancer, non–small cell lung cancer, maintenance treatment, safety management
format	article
author	Herder GJM Codrington H Colder CD Aerts JG
author_facet	Herder GJM Codrington H Colder CD Aerts JG
author_sort	Herder GJM
title	Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases
title_short	Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases
title_full	Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases
title_fullStr	Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases
title_full_unstemmed	Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases
title_sort	practical management of nsclc patients with long-term bevacizumab treatment: a report of four cases
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/5b5fdb05a88e4542a6ff4adb45ba0468
work_keys_str_mv	AT herdergjm practicalmanagementofnsclcpatientswithlongtermbevacizumabtreatmentareportoffourcases AT codringtonh practicalmanagementofnsclcpatientswithlongtermbevacizumabtreatmentareportoffourcases AT coldercd practicalmanagementofnsclcpatientswithlongtermbevacizumabtreatmentareportoffourcases AT aertsjg practicalmanagementofnsclcpatientswithlongtermbevacizumabtreatmentareportoffourcases
_version_	1718401601167687680

Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases

Ejemplares similares